Form 4: Cyclo Therapeutics Director Receives Stock Grant in Lieu of Cash Compensation

William S. Shanahan, a director at Cyclo Therapeutics, received 15,145 shares of common stock in lieu of cash compensation for the third quarter of 2024.

Summary

• William S. Shanahan, a director at Cyclo Therapeutics, received 15,145 shares of common stock on November 15, 2024.
• This stock grant was in lieu of cash compensation for his services as a director during the third quarter of 2024.
• The number of shares was calculated based on the closing price of $0.66 per share on November 14, 2024.
• Following this transaction, Mr. Shanahan directly owns 148,826 shares of Cyclo Therapeutics common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of director compensation, which is generally viewed neutrally to slightly positive as it aligns director interests with shareholders.

Positives

• The grant of shares aligns director compensation with company performance.
• The director's increased stake in the company may signal confidence in its future.

Industry Context

This type of stock grant is a common practice for compensating directors, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock grants in lieu of cash compensation are a common practice among publicly traded companies, particularly for non-employee directors.
• The value of the grant is determined by the company's stock price, which is a standard method for equity-based compensation.
• Many companies in the biotechnology sector use similar compensation strategies to attract and retain board members.

Stakeholder Impact

• Shareholders may view this as a positive sign of director commitment.
• The transaction has a minimal impact on the company's financials.

Key Dates

Keywords

Cyclo Therapeutics, Director Compensation, Stock Grant, Form 4, Insider Trading, Equity Compensation, CYTH